张静, 王晰程, 曹彦硕, 李健, 张小田, 龚继芳, 陆明, 高静, 李艳艳, 沈琳. 二代测序在家族遗传性高危胃肠肿瘤筛查中的应用[J]. 中国肿瘤临床, 2018, 45(19): 1000-1004. DOI: 10.3969/j.issn.1000-8179.2018.19.699
引用本文: 张静, 王晰程, 曹彦硕, 李健, 张小田, 龚继芳, 陆明, 高静, 李艳艳, 沈琳. 二代测序在家族遗传性高危胃肠肿瘤筛查中的应用[J]. 中国肿瘤临床, 2018, 45(19): 1000-1004. DOI: 10.3969/j.issn.1000-8179.2018.19.699
Zhang Jing, Wang Xicheng, Cao Yanshuo, Li Jian, Zhang Xiaotian, Gong Jifang, Lu Ming, Gao Jing, Li Yanyan, Shen Lin. Appolication of next-generation sequencing for the screening of hereditary gastrointestinal cancer[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2018, 45(19): 1000-1004. DOI: 10.3969/j.issn.1000-8179.2018.19.699
Citation: Zhang Jing, Wang Xicheng, Cao Yanshuo, Li Jian, Zhang Xiaotian, Gong Jifang, Lu Ming, Gao Jing, Li Yanyan, Shen Lin. Appolication of next-generation sequencing for the screening of hereditary gastrointestinal cancer[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2018, 45(19): 1000-1004. DOI: 10.3969/j.issn.1000-8179.2018.19.699

二代测序在家族遗传性高危胃肠肿瘤筛查中的应用

Appolication of next-generation sequencing for the screening of hereditary gastrointestinal cancer

  • 摘要:
      目的  探索二代测序技术对家族遗传性高危胃肠肿瘤患者进行遗传筛查的意义及高危因素在筛选患者中的价值。
      方法  选取2016年3月至2016年4月收治于北京大学肿瘤医院的322例结直肠癌及胃癌患者,筛选出25例遗传性胃肠肿瘤高危患者,运用二代测序技术对患者的外周血白细胞DNA进行42个遗传性肿瘤综合征相关基因的胚系检测。
      结果  24%(6/25)患者检测出遗传性肿瘤相关基因的病理性胚系突变,其中50%(3/6)患者肿瘤组织的免疫组织化学检测表现为错配修复蛋白表达缺失,83%(5/6)患者发病年龄≤50岁且具有恶性肿瘤家族史。发生胚系突变的6例遗传性肿瘤相关基因分别为MYH基因错义突变1例,APC基因缺失突变1例和遗传性非息肉病性结直肠癌(hereditary nonpolyposis colorectal cancer,HNPCC)相关基因的突变4例(包括MLH1、MLH3、TGFBR2的错义突变和MSH6的无义突变各1例),且提供了MLH3的胚系致病突变的家系验证。
      结论  通过二代测序技术对本研究入组的25例患者进行家族遗传性肿瘤综合征的筛查,检测出遗传性肿瘤相关基因的胚系致病突变6例,提示运用二代测序技术对家族遗传性高危消化道肿瘤患者进行遗传筛查具有提高检测阳性率的临床应用价值。

     

    Abstract:
      Objective  To explore the significance of next-generation sequencing for the screening of high-risk hereditary gastrointestinal cancer patients and the value of high-risk factors in screening.
      Methods  Twenty-five hereditary high-risk gastrointestinal cancer patients from March 2016 to April 2016 in Peking University Cancer Hospital were enrolled. They received detection of 42 hereditary cancer syndrome related genes by next-generation sequencing.
      Results  Out of 25 patients enrolled, 24% (6/25) patients had pathological germline mutations. The expression of mismatch repair protein was absent in 50% (3/6) patients. There were 83% (5/6) patients with family history of malignant tumors and were diagnosed when younger than 50 years. Six patients had hereditary cancer syndrome related gene mutation, 1 patient had MYH gene missense mutation, 1 patient had APC gene deletion mutation, 4 patients had hereditary colorectal cancer related gene mutation, including MLH1, MLH3, and TGFBR2 germline missense mutations as well as MSH6 nonsense mutation.
      Conclusions  Out of 25 patients with high-risk factors of hereditary gastrointestinal cancer, 6 (24%) had pathological germline mutations. Given the high frequency and wide spectrum of mutations, the application of next-generation sequencing for screening of hereditary high-risk gastrointestinal cancer patients has the clinical value for improving the positive rate of diagnosis.

     

/

返回文章
返回